Navigation Links
EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Date:5/30/2008

DURHAM, N.C., May 30 /PRNewswire/ -- Dr. George C. Clark of Xenobiotic Detection Systems (XDS) and Dr. Michael Denison at the University of California Davis, with support from the Superfund Basic Research Program, have developed a rapid and inexpensive recombinant cell bioassay system for the detection and relative quantification of dioxin-like chemicals. Dioxin-like chemicals are some of the most toxic chemicals known.

The CALUX(R) by XDS (Chemical Activated LUciferase Gene Expression) system has recently been published and is posted under "New Methods" on the SW-846 website. In March 2008, the EPA's Office of Solid Waste (OSW) Organic Methods Workgroup formally reviewed and approved Method 4435 for inclusion into Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, also known as SW-846. The XDS-CALUX system consists of a unique sample processing method linked with a sensitive gene expression cell bioassay detection system providing unique sensitivity and selectivity for quantifying dioxin-like chemicals.

The XDS-CALUX(R) bioassay costs are 40%-70% lower than the traditional High Resolution Gas Chromatography/Mass Spectrometry (HR GC/MS) that was the old singular analysis standard. Xenobiotic Detection Systems Method 4435 provides an excellent screening tool to rapidly detect and quantify these ubiquitous and toxic environmental contaminants.

"This approval exemplifies the assay's versatility and is another major step for XDS," says President of XDS, Dr. George Clark. "Having been certified in the European Union since 2002 to primarily monitor feed and food it is wonderful to receive accreditation here in the U.S. Our screening analysis method is faster, far more affordable, and in many cases even more sensitive than the traditional HR GC/MS. The EPA's approval will allow us to better serve our clients and safeguard the environment from these toxic contaminants."

Research Institutes Worldwide using XDS-CALUX(R) Technology includes the United States: US FDA and University of California Davis. Asia: Hiyoshi Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory, Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy, Poland.

Development of the XDS-CALUX(R) technology was funded in part by Superfund Basic Research Program Grant (ES04699), and by Small Business Innovation Research Grants from the National Institute of Environmental Health Sciences (ES 08372-01 and ES 08372-02).

Additional information: XDS (http://www.dioxins.com) or call 1-888-D-I-O-X-I-N-S

(R) "Registered US Trademark and Patent Office"


'/>"/>
SOURCE Xenobiotic Detection Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... The doctors at ... BC, who live with dental fear and require sedation to receive dental care. The ... ease during various procedures, from hygienic cleanings to oral surgery, at their dental office ...
(Date:4/25/2017)... ... 2017 , ... Back Pain Centers of America (BPC), which connects ... in their area, announces the launch of a new and proprietary customer relationship management ... for reputable physicians to help them with back or neck pain and helps to ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his ... the quarterback position. The former overall number one pick in the 2001 NFL Draft, ... He holds the record for the most career rushing yards by a quarterback (6,109) ...
(Date:4/24/2017)... ... , ... The bar for just about everything—apparel, eyewear, cars and even phone ... pop and film stardom.(1) Not to be left out is that most desired of ... the gamut from being encrusted with jewels and precious metals to, at the very ...
Breaking Medicine News(10 mins):